RXi: results confirm drug's effectiveness
Courtesy of RXi Pharmaceuticals
Marlborough-based biotechnology firm RXi Pharmaceuticals said three-month observations have confirmed the effectiveness of its first product candidate, RXI-109, in the treatment of post-surgical scars.
The results show that when RXI-109 is delivered two weeks after scar-revision surgery, evaluators are better able to identify the area of the scar treated with RXI-109. This supports RXi’s decision to deliver treatment two weeks after surgery, rather than the acute inflammatory phase of the healing process, according to a statement. This confirms initial observations the company announced in September.
The findings are part of the company’s Phase 2a clinical trials of RXI-109 in patients with pre-existing scars of the lower abdomen.
“We are pleased to see that our early observations … are confirmed by our three-month observations," said Geert Cauwenbergh, president and CEO of RXI. “Our work is obviously not done. The observations … allow us to fine tune the treatment schedules in the ongoing adaptive protocols.”
WBJ Web Partners
Most Recent
Most Recent
0 Comments